Amneal Pharmaceuticals, Inc. (AMRX) vs GRAIL Inc. (GRAL)
A side-by-side comparison of Amneal Pharmaceuticals, Inc. and GRAIL Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AMRX
Amneal Pharmaceuticals, Inc.
$20.26HealthcareDelayed quote: Oct 6, 2026, 10:15 AM EDT
GRAL
GRAIL Inc.
$151.56HealthcareDelayed quote: Oct 6, 2026, 10:15 AM EDT
Total return — AMRX vs GRAL
growth of $100 · dividends reinvested · last 2yAMRX +189.5% (+70.1%/yr)GRAL +1028.0% (+235.9%/yr)GRAL compounded faster over this window
AMRX GRAL
AMRX vs GRAL: by the numbers
- •GRAL is the larger company ($6.50B vs $6.47B market cap).
- •AMRX is profitable (5.05% net margin) while GRAL runs a net loss (-236.95%).
Metrics side by side
Valuation
| Metric | AMRX | GRAL |
|---|---|---|
| P/E ratio | 41.56 | N/A |
| Forward P/E | 19.79 | N/A |
| P/S ratio | 2.08 | 39.36 |
| P/B ratio | 195.90 | 2.56 |
| EV / EBITDA | 15.29 | N/A |
| FCF yield | 1.28% | N/A |
Profitability
| Metric | AMRX | GRAL |
|---|---|---|
| Gross margin | 39.32% | -42.52% |
| Operating margin | 12.93% | -362.95% |
| Net margin | 5.05% | -236.95% |
| ROE | 476.51% | -15.40% |
| ROIC | 13.45% | -20.26% |
Growth (annualized)
| Metric | AMRX | GRAL |
|---|---|---|
| Revenue CAGR (5Y) | 8.67% | N/A |
| EPS CAGR (5Y) | -17.72% | N/A |
| FCF CAGR (5Y) | -14.46% | N/A |
| Total return CAGR (5Y) | 30.25% | N/A |
Frequently asked
- Is AMRX or GRAL more profitable?
- AMRX runs the higher net margin — AMRX at 5.05% versus GRAL at -236.95%.
Go deeper
Dig into the metrics
Amneal Pharmaceuticals P/E ratioAmneal Pharmaceuticals ROEGRAIL ROEAmneal Pharmaceuticals operating marginGRAIL operating marginAmneal Pharmaceuticals revenue growthGRAIL revenue growthAmneal Pharmaceuticals free cash flowGRAIL free cash flow
Amneal Pharmaceuticals & GRAIL appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.